The company invented Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been ...

China is the fourth major market in which the treatment, sold under the brand name Kisunla, has received approval after the ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...

Medicare Part B covers Leqembi for people with early Alzheimer's or mild cognitive impairment. Learn more about Leqembi and Medicare coverage here.

China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The ...

Australia's corporate watchdog on Wednesday said it has sued trading platform Binance Australia Derivatives, alleging that ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.

Biogen Inc. (NASDAQ:BIIB), currently trading near its 52-week low at $156.19, finds itself at a critical juncture as it navigates the launch of its Alzheimer's treatment Leqembi while grappling ...

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...